Core Viewpoint - The announcement details the upcoming listing and circulation of restricted shares for Suzhou Saifen Technology Co., Ltd., which will occur on July 10, 2025, following the expiration of a six-month lock-up period for shares allocated through offline placement [1][2]. Group 1: Listing Details - The total number of shares to be listed is 2,975,050, representing 0.71% of the company's total share capital [4]. - The shares are part of the company's initial public offering (IPO) and are subject to a six-month lock-up period that began on January 10, 2025 [2][3]. - The company received approval from the China Securities Regulatory Commission for its IPO, allowing it to issue a total of 49,975,690 shares, with a total share capital of 416,464,084 shares post-IPO [1][2]. Group 2: Shareholder Commitments - Shareholders of the restricted shares have committed to a lock-up period of six months, with 10% of their allocated shares subject to this restriction [2][3]. - As of the announcement date, all shareholders have adhered to their commitments, ensuring no issues that would affect the upcoming circulation of restricted shares [2][3]. Group 3: Underwriter's Verification - The underwriter, CITIC Securities Co., Ltd., has confirmed that all shareholders have complied with their lock-up commitments, and the details regarding the circulation of restricted shares meet regulatory requirements [3].

证券代码：300972 证券简称：万辰集团 公告编号：2025-049 福建万辰生物科技集团股份有限公司 关于 2023 年限制性股票激励计划第二个归属期（第一批次）及 次）归属结果暨股份上市的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 重要内容提示： 年限制性股票激励计划第二个归属期（第一批次）激励对象：10 人，2024 年限 制性股票激励计划首次授予部分第一个归属期（第一批次）激励对象：7 人） 量：453.3301 万股，2024 年限制性股票激励计划首次授予部分第一个归属期（第 一批次）拟归属数量：309.2000 万股） A 股普通股股票 根据福建万辰生物科技集团股份有限公司（以下简称"公司"或"万辰集团"） 于 2025 年 6 月 23 日召开的第四届董事会第二十七次会议和第四届监事会第二 十八次会议，分别审议通过了《关于公司 2023 年限制性股票激励计划第二个归 属期（第一批次）归属条件成就的议案》《关于公司 2024 年限制性股票激励计 划首次授予部分第一个归属期（第一批次）归属条件成就的议案》。近日公司办 理了 2023 年 ...

Core Viewpoint - The CESHKB index has shown significant growth, with a year-to-date increase of 64.30%, indicating a strong performance in the biotechnology sector listed in Hong Kong [1][2]. Group 1: Index Performance - The CESHKB index opened high and fluctuated, closing at 7388.22 points with a trading volume of 12.985 billion [1]. - Over the past month, the CESHKB index has risen by 14.05%, and over the last three months, it has increased by 17.80% [1]. Group 2: Index Composition - The CESHKB index is compiled by China Securities Index Co., Ltd. under the commission of China Securities Trading Service Co., Ltd., reflecting the overall performance of biotechnology companies listed in Hong Kong [1]. - The top ten holdings in the CESHKB index include: - CanSino Biologics (10.49%) - Innovent Biologics (9.9%) - WuXi Biologics (9.73%) - 3SBio (8.86%) - BeiGene (8.81%) - Zai Lab (5.86%) - WuXi AppTec (5.85%) - Kelun-Biotech (5.1%) - Genscript Biotech (4.42%) - Ascentage Pharma-B (4.15%) [1]. Group 3: Market and Industry Overview - The CESHKB index is entirely composed of companies listed on the Hong Kong Stock Exchange, with a 100% representation in the healthcare sector [2].

Market Overview - Major industry ETFs in the US experienced a decline, with the global airline industry ETF down by 0.9%, the healthcare ETF down by 0.72%, and the utilities ETF down by 0.67% [1] Industry Performance - The global airline industry ETF is priced at $23.22, reflecting a decrease of $0.21 or 0.90% with a trading volume of 43,489 shares and a total market value of $73.14 million, showing an 8.40% decline year-to-date [2] - The healthcare ETF is priced at $135.73, down by $0.98 or 0.72%, with a trading volume of 676,100 shares and a total market value of $259.74 billion, indicating a year-to-date decrease of 0.48% [2] - The utilities ETF is priced at $81.39, down by $0.55 or 0.67%, with a trading volume of 942,700 shares and a total market value of $11.81 billion, reflecting a year-to-date increase of 9.05% [2] - The financial sector ETF is priced at $52.48, down by $0.18 or 0.34%, with a trading volume of 2.23 million shares and a total market value of $584.13 billion, showing a year-to-date increase of 9.35% [2] - The technology sector ETF is priced at $250.50, down by $0.47 or 0.19%, with a trading volume of 254,600 shares and a total market value of $796.73 billion, indicating a year-to-date increase of 8.10% [2] - The energy sector ETF is priced at $85.78, up by $0.32 or 0.37%, with a trading volume of 1.09 million shares and a total market value of $21.48 billion, reflecting a year-to-date increase of 1.74% [2]

Group 1 - The core focus of the market will be on sectors related to information technology and telecommunications, healthcare and pharmaceuticals, as well as retail, consumer goods, and services [1][3] Group 2 - The Hong Kong IPO market has significantly rebounded in the first half of the year, raising HKD 107.1 billion, a sevenfold increase compared to the same period last year, surpassing the total fundraising amount for the entire year of 2024 [2] - In the first half of the year, 44 new stocks were listed in Hong Kong, with 42 on the main board, primarily in retail, consumer goods, and services, which accounted for 34% of the listings [2] - PwC anticipates that the positive market sentiment will continue into the second half of the year, with over 200 companies having submitted applications to list in Hong Kong, covering traditional industries as well as new economy sectors like biotechnology, healthcare, and artificial intelligence [2][3] Group 3 - By the end of December 2024, there are 3 specialized technology companies under Chapter 18C and 67 biotechnology companies under Chapter 18A on the Hong Kong Stock Exchange [3] - Following the launch of the "Special Line for Science and Technology Enterprises" in May 2025, the number of biotechnology companies listed is expected to increase to 73 by June 2025 [3] - PwC predicts that 90 to 100 companies will be listed in Hong Kong in 2025, with fundraising expected to exceed HKD 200 billion, focusing on information technology and telecommunications, healthcare and pharmaceuticals, and retail, consumer goods, and services sectors [3]

Investment Rating - The report assigns a "Buy" rating to the company, with a target price of HKD 72.50, indicating a potential upside of 16.6% from the current closing price of HKD 62.20 [1][27]. Core Insights - The mRNA platform development is progressing steadily, with excellent data on the reversible BTK inhibitor for membranous nephropathy. The target price has been raised to reflect these developments [2][6]. - The company has showcased its fully integrated and localized AI + mRNA platform, highlighting several mRNA tumor drug developments, including personalized and universal therapeutic vaccines [6]. - The reversible BTK inhibitor EVER001 has shown promising results in clinical trials for treating membranous nephropathy, with significant reductions in anti-PLA2R antibody levels and urinary protein levels [6]. Financial Overview - Revenue projections for the company are as follows: - 2023: RMB 126 million - 2024: RMB 707 million - 2025E: RMB 1,660 million - 2026E: RMB 2,552 million - 2027E: RMB 3,752 million - Year-on-year growth rates are projected at 884.5% for 2023, 461.2% for 2024, and 134.9% for 2025 [5][28]. - The net profit (loss) is expected to improve from a loss of RMB 844 million in 2023 to a profit of RMB 743 million by 2027 [5][28]. - The company’s market capitalization is approximately HKD 20.2 billion, with an average daily trading volume of 13.36 million shares [3]. Valuation Metrics - The report indicates a peak sales estimate for EVER001 exceeding RMB 1.5 billion, with a target valuation of HKD 72.50 corresponding to a market cap of HKD 237 billion and a price-to-sales ratio of 1.8 times at peak revenue [6][24]. - The company’s financial forecasts have been adjusted, reflecting a more cautious outlook on product revenue ramp-up, with slight downward revisions in revenue estimates for 2025-2027 [6][23].

Core Viewpoint - Hubei province is leveraging institutional innovation to address financing challenges faced by small and micro enterprises and technology companies, creating a collaborative financial ecosystem involving government, banks, and businesses [1] Group 1: Financing Challenges - Small and micro enterprises often struggle with financing due to a lack of effective collateral, leading to cash flow issues, as highlighted by the chairman of Wuhan Bowang Xinyuan Environmental Technology Co., Ltd [2] - The financing difficulties are attributed to three main pain points: the challenge of assessing intangible assets like commercial value and patents, information asymmetry between banks and enterprises, and the high risk management difficulty for financial institutions [2][3] Group 2: Innovative Solutions - Hubei has implemented a provincial platform called "E-Rong Tong" and a "smart brain" system to break down data barriers across various departments, enabling precise credit profiling for enterprises [3] - The introduction of commercial value credit loans has allowed companies like Bowang Xinyuan to secure significant funding based on their credit ratings, demonstrating the effectiveness of the new financing policies [2][3] Group 3: Implementation and Impact - The Shanghai Pudong Development Bank (SPDB) Wuhan Branch has successfully transitioned its credit evaluation from fixed asset-based to innovation capability-based, facilitating quicker loan approvals for technology-driven companies [4] - The "Pu Hui Lai Le" app has been launched to provide comprehensive financial services for small and micro enterprises, enabling a streamlined online loan application process [4] - As of June 30, 2023, the SPDB Wuhan Branch has served 195 clients with knowledge value credit loans, totaling 11.981 billion yuan in credit, and 4.258 billion yuan in disbursed loans [5] Group 4: Ecosystem Development - The provincial support for small and micro enterprises has been continuously improving, leading to enhanced financing efficiency and reduced costs for companies [6][7] - The "knowledge value credit loan" and "commercial value credit loan" models are fostering a positive reaction in Hubei, with a significant number of technology enterprises benefiting from these initiatives [7] - The "smart brain" platform has attracted 21 financial institutions and offers a wide range of 51 technology financial products, indicating a robust ecosystem for innovation financing [7]

美国哈佛大学领导的研究团队设计并测试了一种称为"赛博胚胎"的柔性电极神经信号记录平台。这是一 种专为发育中的大脑"量身打造"的生物电子平台，可通过胚胎发育实现全脑探针植入。其有望揭示胚胎 是如何随发育逐步建立起神经环路的，以及神经环路与复杂行为之间的关联。该成果在神经科学领域具 有里程碑意义，相关研究作为封面文章发表在新一期《自然》杂志上。 该平台已应用于多种脊椎动物模型，包括非洲爪蟾胚胎、小鼠胚胎和新生大鼠神经系统，在不同物种中 实现了稳定的电生理记录。特别是在脊髓损伤再生实验中，研究团队观察到类似发育过程的神经活动模 式，显示出该系统在再生医学领域的广泛应用前景。 这一成果被认为是首个实现对非透明胚胎中发育期大脑活动进行毫秒级电生理记录的技术突破，为研究 神经发育机制、理解相关疾病以及推动脑机接口技术发展提供了全新工具。 （文章来源：科技日报） 研究团队从发育生物学中获得启发，利用脊椎动物胚胎发育过程中"神经胚形成"阶段的自然变化，将超 薄、可拉伸的电极阵列嵌入胚胎神经板中。随着神经管闭合，电极也随之折叠、展开，最终与三维脑组 织高度整合。实验表明，这一方法不仅实现了无缝集成，还不会干扰大脑的正常发育和功 ...

Core Points - The company has approved a profit distribution and capital reserve transfer plan for the fiscal year 2024, which includes a cash dividend and a stock increase for shareholders [1][2] Profit Distribution and Capital Reserve Transfer Plan - The profit distribution plan involves a cash dividend of 1.00 RMB per 10 shares, totaling 8,039,732.30 RMB (including tax), based on a total share capital of 80,397,323 shares [1][2] - The company will not issue bonus shares but will increase the share capital by transferring 4 shares for every 10 shares held, resulting in an increase of 32,158,929 shares, bringing the total share capital to 112,556,252 shares [1][2] Dividend Payment Date and Recipients - The dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shenzhen Branch as of July 9, 2025 [3] Share Capital Structure Changes - Before the distribution, the total share capital was 80,397,323 shares, and after the transfer, it will be 112,556,252 shares [4] - The company will handle any legal responsibilities related to cash dividend distribution [3] Adjustments and Consultations - The company will adjust relevant parameters post-distribution, including the minimum selling price for shares after the ex-dividend date, set at 55.56 RMB per share [4] - For inquiries, the company has provided contact details for its securities department [6]

Market Overview - Major industry ETFs mostly declined, with the Consumer Discretionary ETF down approximately 1%, the Biotechnology Index ETF down 0.55%, and the Energy ETF down 0.5% [1] Industry Performance - Consumer Discretionary ETF (US XLY) current price: $215.37, down $1.96 (-0.90%), with a trading volume of 86,452 shares and a total market value of $27.051 billion, down 3.53% year-to-date [2] - Biotechnology Index ETF (US IBB) current price: $125.81, down $0.70 (-0.55%), with a trading volume of 54,019 shares and a total market value of $9.989 billion, down 4.76% year-to-date [2] - Energy ETF (US XLE) current price: $84.39, down $0.42 (-0.50%), with a trading volume of 1.0193 million shares and a total market value of $21.133 billion, up 0.09% year-to-date [2] - Semiconductor ETF (US SMH) current price: $277.65, down $1.23 (-0.44%), with a trading volume of 248,700 shares and a total market value of $3.282 billion, up 14.65% year-to-date [2] - Internet Index ETF (US FDN) current price: $268.48, down $0.85 (-0.31%), with a trading volume of 2,192 shares and a total market value of $17.827 billion, up 10.41% year-to-date [2] - Global Technology ETF (US IXN) current price: $92.09, down $0.25 (-0.27%), with a trading volume of 3,645 shares and a total market value of $1.289 billion, up 8.87% year-to-date [2] - Banking ETF (US KBE) current price: $55.67, down $0.09 (-0.16%), with a trading volume of 32,613 shares and a total market value of $4.309 billion, up 1.77% year-to-date [2] - Technology Sector ETF (US XLK) current price: $252.89, down $0.34 (-0.13%), with a trading volume of 158,800 shares and a total market value of $804.33 billion, up 9.13% year-to-date [2] - Healthcare ETF (US XLV) current price: $134.61, down $0.18 (-0.13%), with a trading volume of 326,900 shares and a total market value of $25.760 billion, down 1.30% year-to-date [2] - Financials ETF (US XLF) current price: $52.31, down $0.06 (-0.11%), with a trading volume of 890,000 shares and a total market value of $58.223 billion, up 9.00% year-to-date [2] - Global Airlines ETF (US JETS) current price: $22.95, down $0.02 (-0.09%), with a trading volume of 42,334 shares and a total market value of $72.293 million, down 9.47% year-to-date [2] - Utilities ETF (US XLU) current price: $81.60, down $0.06 (-0.07%), with a trading volume of 595,900 shares and a total market value of $11.846 billion, up 9.33% year-to-date [2] - Regional Banks ETF (US KRE) current price: $59.42, up $0.03 (+0.05%), with a trading volume of 263,600 shares and a total market value of $4.959 billion, down 0.20% year-to-date [2] - Consumer Staples ETF (US XLP) current price: $81.33, up $0.36 (+0.44%), with a trading volume of 459,700 shares and a total market value of $137.63 million [2]